Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Lung Cancer

Free Subscription Articles published in JAMA Oncol Retrieve available abstracts of 40 articles: HTML format Text format

Single Articles

September 2019
1. SYKES DB
   Insights From a Patient With Lung Cancer-Party Therapy Is Way Better Than Chemotherapy.
   JAMA Oncol. 2019 Sep 12. pii: 2749689. doi: 10.1001/jamaoncol.2019.2591.
   PubMed     Text format    
   
   
   
2. YIN G, Zhang C
   Reanalysis of Data Comparing Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer.
   JAMA Oncol. 2019 Sep 5. pii: 2749254. doi: 10.1001/jamaoncol.2019.3593.
   PubMed     Text format    
   
   
   
3. SUN A, Hu C
   Reanalysis of Data Comparing Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer-In Reply.
   JAMA Oncol. 2019 Sep 5. pii: 2749255. doi: 10.1001/jamaoncol.2019.3602.
   PubMed     Text format    
   
   
   August 2019
4. RENGAN R, Mick R, Pryma DA, Lin LL, et al
   Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer: A Phase 1/2 Trial.
   JAMA Oncol. 2019 Aug 22. pii: 2748893. doi: 10.1001/jamaoncol.2019.2095.
   PubMed     Text format     Abstract available
   
   
   
5. CATANIA C, Del Signore E, Spitaleri G
   The Desire for Life and Motherhood Despite Metastatic Lung Cancer.
   JAMA Oncol. 2019 Aug 15. pii: 2748397. doi: 10.1001/jamaoncol.2019.2588.
   PubMed     Text format    
   
   
   
6. STINCHCOMBE TE, Janne PA, Wang X, Bertino EM, et al
   Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
   JAMA Oncol. 2019 Aug 8. pii: 2747878. doi: 10.1001/jamaoncol.2019.1847.
   PubMed     Text format     Abstract available
   
   
   July 2019
7. TOPALIAN SL, Hodi FS, Brahmer JR, Gettinger SN, et al
   Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab.
   JAMA Oncol. 2019 Jul 25. pii: 2738775. doi: 10.1001/jamaoncol.2019.2187.
   PubMed     Text format     Abstract available
   
   
   
8. KAZANDJIAN D, Gong Y, Keegan P, Pazdur R, et al
   Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer.
   JAMA Oncol. 2019 Jul 25. pii: 2738768. doi: 10.1001/jamaoncol.2019.1747.
   PubMed     Text format     Abstract available
   
   
   
9. BAUML JM, Mick R, Ciunci C, Aggarwal C, et al
   Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial.
   JAMA Oncol. 2019 Jul 11. pii: 2738063. doi: 10.1001/jamaoncol.2019.1449.
   PubMed     Text format     Abstract available
   
   
   
10. THEELEN WSME, Peulen HMU, Lalezari F, van der Noort V, et al
    Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.
    JAMA Oncol. 2019 Jul 11. pii: 2738064. doi: 10.1001/jamaoncol.2019.1478.
    PubMed     Text format     Abstract available
    
    
    June 2019
11. ALDRICH MC, Mercaldo SF, Sandler KL, Blot WJ, et al
    Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers.
    JAMA Oncol. 2019 Jun 27. pii: 2737091. doi: 10.1001/jamaoncol.2019.1402.
    PubMed     Text format     Abstract available
    
    
    
12. SALEM A, Faivre-Finn C
    Time to Change the Limited-Stage Paradigm for Small Cell Lung Cancer?-In Reply.
    JAMA Oncol. 2019 Jun 20. pii: 2736365. doi: 10.1001/jamaoncol.2019.1332.
    PubMed     Text format    
    
    
    
13. CHUN SG, Schild SE, Bogart JA
    Time to Change the Limited-Stage Paradigm for Small Cell Lung Cancer?
    JAMA Oncol. 2019 Jun 20. pii: 2736364. doi: 10.1001/jamaoncol.2019.1326.
    PubMed     Text format    
    
    
    May 2019
14. GIRI S, Huntington SF
    Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non-Small Cell Lung Cancer.
    JAMA Oncol. 2019 May 16. pii: 2733792. doi: 10.1001/jamaoncol.2019.1088.
    PubMed     Text format    
    
    
    
15. CRISS SD, Mooradian MJ, Kong CY
    Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non-Small Cell Lung Cancer-In Reply.
    JAMA Oncol. 2019 May 16. pii: 2733793. doi: 10.1001/jamaoncol.2019.1100.
    PubMed     Text format    
    
    
    April 2019
16. BERNER F, Bomze D, Diem S, Ali OH, et al
    Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.
    JAMA Oncol. 2019 Apr 25. pii: 2731134. doi: 10.1001/jamaoncol.2019.0402.
    PubMed     Text format     Abstract available
    
    
    March 2019
17. MOR V, Wagner TH, Levy C, Ersek M, et al
    Association of Expanded VA Hospice Care With Aggressive Care and Cost for Veterans With Advanced Lung Cancer.
    JAMA Oncol. 2019 Mar 28. pii: 2729064. doi: 10.1001/jamaoncol.2019.0081.
    PubMed     Text format     Abstract available
    
    
    
18. SUN A, Hu C, Wong SJ, Gore E, et al
    Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Long-term Update of the NRG Oncology/RTOG 0214 Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2019 Mar 14. pii: 2728245. doi: 10.1001/jamaoncol.2018.7220.
    PubMed     Text format     Abstract available
    
    
    February 2019
19. WANG Z, Duan J, Cai S, Han M, et al
    Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
    JAMA Oncol. 2019 Feb 28. pii: 2726029. doi: 10.1001/jamaoncol.2018.7098.
    PubMed     Text format     Abstract available
    
    
    
20. PALMA DA, Nguyen TK, Louie AV, Malthaner R, et al
    Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.
    JAMA Oncol. 2019 Feb 21. pii: 2725402. doi: 10.1001/jamaoncol.2018.6993.
    PubMed     Text format     Abstract available
    
    
    December 2018
21. TOI Y, Sugawara S, Sugisaka J, Ono H, et al
    Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    JAMA Oncol. 2018 Dec 27. pii: 2718925. doi: 10.1001/jamaoncol.2018.5860.
    PubMed     Text format     Abstract available
    
    
    
22. CRISS SD, Mooradian MJ, Sheehan DF, Zubiri L, et al
    Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
    JAMA Oncol. 2018 Dec 13. pii: 2718006. doi: 10.1001/jamaoncol.2018.5449.
    PubMed     Text format     Abstract available
    
    
    
23. SALEM A, Mistry H, Hatton M, Locke I, et al
    Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial.
    JAMA Oncol. 2018 Dec 6:e185335. doi: 10.1001/jamaoncol.2018.5335.
    PubMed     Text format     Abstract available
    
    
    
24. WEST HJ
    Moving Beyond Limited and Extensive Staging of Small Cell Lung Cancer.
    JAMA Oncol. 2018 Dec 6. pii: 2717231. doi: 10.1001/jamaoncol.2018.5187.
    PubMed     Text format    
    
    
    November 2018
25. CHEN XZ
    Anlotinib for Refractory Advanced Non-Small Cell Lung Cancer in China.
    JAMA Oncol. 2018 Nov 29. pii: 2716809. doi: 10.1001/jamaoncol.2018.5526.
    PubMed     Text format    
    
    
    
26. SLOAN L, Romo CG, Hales RK
    Hemifacial Hyperhidrosis in a Patient With an Apical Non-Small Cell Lung Cancer.
    JAMA Oncol. 2018 Nov 15. pii: 2713851. doi: 10.1001/jamaoncol.2018.4597.
    PubMed     Text format    
    
    
    October 2018
27. EZE C, Kasmann L, Manapov F
    Redefining the Role of Prophylactic Cranial Irradiation in the Modern Era of Active Surveillance in Small Cell Lung Cancer.
    JAMA Oncol. 2018 Oct 25. pii: 2707226. doi: 10.1001/jamaoncol.2018.4833.
    PubMed     Text format    
    
    
    
28. GYAWALI B, West HJ
    Plasma vs Tissue Next-Generation Sequencing in Non-Small Cell Lung Cancer-Either, Both, or Neither?
    JAMA Oncol. 2018 Oct 11. pii: 2705603. doi: 10.1001/jamaoncol.2018.4304.
    PubMed     Text format    
    
    
    
29. AGGARWAL C, Thompson JC, Black TA, Katz SI, et al
    Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.
    JAMA Oncol. 2018 Oct 11. pii: 2705609. doi: 10.1001/jamaoncol.2018.4305.
    PubMed     Text format     Abstract available
    
    
    
30. BOOZALIS E, Kwatra SG, Marrone KA
    Bilateral Lower Extremity Skin Eruptions in an HIV-Positive Man Receiving Pembrolizumab Monotherapy for Non-Small Cell Lung Cancer.
    JAMA Oncol. 2018 Oct 4. pii: 2704206. doi: 10.1001/jamaoncol.2018.4485.
    PubMed     Text format    
    
    
    September 2018
31. TUMINELLO S, Schwartz RM, Liu B, Mhango G, et al
    Opioid Use After Open Resection or Video-Assisted Thoracoscopic Surgery for Early-Stage Lung Cancer.
    JAMA Oncol. 2018 Sep 24. pii: 2703444. doi: 10.1001/jamaoncol.2018.4387.
    PubMed     Text format    
    
    
    
32. FERRARA R, Mezquita L, Texier M, Lahmar J, et al
    Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
    JAMA Oncol. 2018 Sep 6. pii: 2698845. doi: 10.1001/jamaoncol.2018.3676.
    PubMed     Text format     Abstract available
    
    
    August 2018
33. GRIDELLI C, de Castro Carpeno J, Dingemans AC, Griesinger F, et al
    Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.
    JAMA Oncol. 2018 Aug 30:e183486. doi: 10.1001/jamaoncol.2018.3486.
    PubMed     Text format     Abstract available
    
    
    
34. HAN B, Li K, Wang Q, Zhang L, et al
    Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2018 Aug 9. pii: 2696341. doi: 10.1001/jamaoncol.2018.3039.
    PubMed     Text format     Abstract available
    
    
    
35. ALCORN SR, Miller DB, Hales RK
    Underutilization of Combined-Modality Therapy in Limited-Stage Small Cell Lung Cancer.
    JAMA Oncol. 2018 Aug 2. pii: 2694876. doi: 10.1001/jamaoncol.2018.3261.
    PubMed     Text format    
    
    
    
36. PASQUINELLI MM, Kovitz KL, Koshy M, Menchaca MG, et al
    Outcomes From a Minority-Based Lung Cancer Screening Program vs the National Lung Screening Trial.
    JAMA Oncol. 2018 Aug 2. pii: 2694875. doi: 10.1001/jamaoncol.2018.2823.
    PubMed     Text format    
    
    
    
37. CHUN SG, Pezzi TA, Schwartz DL
    Underutilization of Combined-Modality Therapy in Limited-Stage Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2018 Aug 2. pii: 2694877. doi: 10.1001/jamaoncol.2018.3292.
    PubMed     Text format    
    
    
    
38. OXNARD GR, Hu Y, Mileham KF, Husain H, et al
    Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.
    JAMA Oncol. 2018 Aug 2. pii: 2694879. doi: 10.1001/jamaoncol.2018.2969.
    PubMed     Text format     Abstract available
    
    
    July 2018
39. GUIDA F, Sun N, Bantis LE, Muller DC, et al
    Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins.
    JAMA Oncol. 2018 Jul 12:e182078. doi: 10.1001/jamaoncol.2018.2078.
    PubMed     Text format     Abstract available
    
    
    June 2018
40. GANDARA DR, Riess JW, Lara PN Jr
    In Search of an Oncogene Driver for Squamous Lung Cancer.
    JAMA Oncol. 2018 Jun 14. pii: 2684629. doi: 10.1001/jamaoncol.2018.0774.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: